Medical Patent News RSS Feed - Medical Patent News

USITC rules out patent claims on Apex's CPAP-complimentary mask

USITC rules out patent claims on Apex's CPAP-complimentary mask

Apex Medical Corporation a leading player in the Respiratory Therapy and Pressure Area Care sectors, announced that it has successfully obtained an initial advisory opinion from the United States International Trade Commission (USITC) that its continuous positive airway pressure (CPAP)-complimentary mask product is free from patent claims previously asserted by its Australia-based competitor, ResMed. [More]
Actavis signs deal with Cephalon to settle patent litigation related to Nuvigil tablets

Actavis signs deal with Cephalon to settle patent litigation related to Nuvigil tablets

Actavis plc today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil® (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). [More]
USPTO grants two additional patents to SeroVital-hgh formula

USPTO grants two additional patents to SeroVital-hgh formula

SeroVital®-hgh, the "Fountain of Youth" Formula everyone's talking about, has been making headlines ever since a group of some of the most renowned researchers in the world revealed that this oral compound is actually capable of increasing mean, endogenous, serum (blood) human growth hormone (hGH) levels by 682%. Experts everywhere — from dermatologists and obesity researchers to women's healthcare providers and even the famed Dr. Oz himself — began paying attention to this groundbreaking formula. [More]
OxThera granted new patents for treatment of hyperoxaluria

OxThera granted new patents for treatment of hyperoxaluria

OxThera AB announced today that it has been granted two new US patents and one new Australian patent during the last year. [More]
Baylor receives patent for islet cell transplantation in patients with type1 diabetes, chronic pancreatitis

Baylor receives patent for islet cell transplantation in patients with type1 diabetes, chronic pancreatitis

Baylor Research Institute has been awarded a patent from the U.S. Patent Office for a potential strategy to improve the outcomes of islet cell transplantation for patients with type 1 diabetes and chronic pancreatitis. [More]
Three NSU professors secure patents for their innovations

Three NSU professors secure patents for their innovations

Three Nova Southeastern University's (NSU) professors from three different colleges recently secured patents for their innovations. [More]
USPTO issues three new patents to Discovery Laboratories

USPTO issues three new patents to Discovery Laboratories

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent and Notices of Allowance for patents covering critical aspects of its KL4 surfactant and drug delivery technology platform. [More]
TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to TWi's lidocaine topical patch 5% product. [More]
Top performing oncology drugs at risk of losing patent rights by 2022

Top performing oncology drugs at risk of losing patent rights by 2022

After a period of relative stability, a glut of patent expiries is just five years away for the oncology market, according to pharmaceutical analyst Datamonitor Healthcare. [More]
Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Mylan Inc. today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Frovatriptan Succinate Tablets, 2.5 mg. [More]

LifeBond granted Chinese patent for novel absorbable surgical adhesive technology

LifeBond Ltd., a leading developer of absorbable biosurgical products for tissue repair, announced today that the State Intellectual Property Office of the People's Republic of China has granted the company its first Chinese patent. [More]
USPTO grants patent for low-cost dry powder inhaler to Hovione

USPTO grants patent for low-cost dry powder inhaler to Hovione

Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application. [More]
U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent"). [More]
Actavis gets favorable ruling in patent suit against generic Lialda

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). [More]
Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against membrane protein targets. [More]
GLNT receives allowance of patent for Parkinson's disease monitoring technology

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment. [More]
Actavis files ANDA with FDA to market  Colchicine Tablets USP

Actavis files ANDA with FDA to market Colchicine Tablets USP

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. [More]
Zimmer issues 5 new patents directed to Subchondroplasty Procedure

Zimmer issues 5 new patents directed to Subchondroplasty Procedure

Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today announced that the United States Patent and Trademark Office has issued five new patents directed to the Subchondroplasty® Procedure, the innovative new joint preservation procedure developed by Zimmer Knee Creations: U.S. Patent No. 8,551,178, U.S. Patent No. 8,574,303, U.S. Patent No. 8,608,802, U.S. Patent No. 8,617,166 and U.S. Patent No. 8,623,089. [More]
New drug patent may help overcome problems associated with MDR-TB

New drug patent may help overcome problems associated with MDR-TB

A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria once again responsive to antibiotics. [More]
Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery." [More]